表紙
市場調查報告書

子宮內膜癌治療藥的全球市場:2018年∼2022年

Global Endometrial Cancer Therapeutics Market 2018-2022

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 707382
出版日期 內容資訊 英文 110 Pages
訂單完成後即時交付
價格
子宮內膜癌治療藥的全球市場:2018年∼2022年 Global Endometrial Cancer Therapeutics Market 2018-2022
出版日期: 2018年09月18日內容資訊: 英文 110 Pages
簡介

關於子宮內膜癌

子宮內膜癌是一種子宮癌,源於形成女性子宮內膜的細胞層。如閉經中的雌激素補充療法一樣沒有黃體酮的拮抗作用狀態的子宮內膜雌激素暴露,與女性患子宮內膜癌的風險增加有關。

Technavio的分析師預測,從2018年到2022年之間,全球子宮內膜癌治療方法市場將以5.17%的年複合成長率成長。

本報告提供全球子宮內膜癌治療方法市場相關調查分析,市場規模與成長率,市場趨勢,市場的推動要素與課題,市場機會驗證,主要供應商等相關的系統性資訊。

目錄

第1章 摘要整理

第2章 調查範圍

第3章 調查方法

第4章 市場情形

  • 市場生態系統
  • 市場特性
  • 市場區隔分析

第5章 市場規模

  • 市場定義
  • 市場規模(2017年)
  • 市場規模及預測(2017-2022年)

第6章 波特的五力分析

  • 買主談判力
  • 供應商談判力
  • 新加入廠商的威脅
  • 替代品的威脅
  • 競爭對手的威脅
  • 市場情形

第7章 開發平台

第8章 市場區隔:各產品

  • 市場區隔:各產品(2017-2022年)
  • 比較:各產品
  • 化療
  • 荷爾蒙療法
  • 市場機會:各產品

第9章 客戶形勢

第10章 地區形勢

  • 各地區市場區隔(2017-2022年)
  • 地區比較
  • 南北美洲
  • 歐洲、中東、非洲地區
  • 亞太地區
  • 市場機會

第11章 決策架構

第12章 成長要素與課題

  • 市場成長要素
  • 市場課題

第13章 市場趨勢

  • 免疫療法
  • 個體化醫療
  • 醫藥品開發平台中小分子的增加

第14章 業者情勢

  • 概要
  • 創造性破壞狀況

第15章 供應商分析

  • 交易廠商
  • 供應商分類
  • 供應商的市場定位
  • CELGENE
  • Janssen Pharmaceuticals
  • Novartis
  • Pfizer
  • Teva Pharmaceutical Industries

第16章 附錄

  • 簡稱的清單
目錄
Product Code: IRTNTR23738

About Endometrial Cancer

Endometrial cancer is a type of uterine cancer, which begins in the layer of cells that form the lining (endometrium) of the uterus of women. Unopposed endometrial estrogen exposure such as estrogen replacement therapy during menopause is associated with increased risk of developing endometrial cancer among women.

Technavio's analysts forecast the Global Endometrial Cancer Therapeutics Market to grow at a CAGR of 5.17% during the period 2018-2022.

Covered in this report

The report covers the present scenario and the growth prospects of the endometrial cancer therapeutics market. To calculate the market size, the report considers the revenue generated by treatment of endometrial cancer across the globe.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Endometrial Cancer Therapeutics Market 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • CELGENE
  • Janssen Pharmaceuticals
  • Novartis
  • Pfizer
  • Teva Pharmaceutical Industries
  • Market driver
  • Increasing prevalence of endometrial cancer
  • For a full, detailed list, view our report

Market challenge

  • High cost associated with treatment
  • For a full, detailed list, view our report

Market trend

  • Immune therapy
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2022 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 05: MARKET SIZING

  • Market definition
  • Market sizing 2017
  • Market size and forecast 2017-2022

PART 06: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 07: PIPELINE

PART 08: MARKET SEGMENTATION BY PRODUCT

  • Segmentation by product
  • Comparison by product
  • Chemotherapy - Market size and forecast 2017-2022
  • Hormone therapy - Market size and forecast 2017-2022
  • Market opportunity by product

PART 09: CUSTOMER LANDSCAPE

PART 10: REGIONAL LANDSCAPE

  • Geographical segmentation
  • Regional comparison
  • Americas - Market size and forecast 2017-2022
  • EMEA - Market size and forecast 2017-2022
  • APAC - Market size and forecast 2017-2022
  • Market opportunity

PART 11: DECISION FRAMEWORK

PART 12: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 13: MARKET TRENDS

  • Immune therapy
  • Personalized medicine
  • Increase in small molecules in drug development pipeline

PART 14: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption

PART 15: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • CELGENE
  • Janssen Pharmaceuticals
  • Novartis
  • Pfizer
  • Teva Pharmaceutical Industries

PART 16: APPENDIX

  • List of abbreviations

List of Exhibits

  • Exhibit 01: Parent market
  • Exhibit 02: Global uterine cancer therapeutics market segmentation
  • Exhibit 03: Market characteristics
  • Exhibit 04: Market segments
  • Exhibit 05: Market definition - Inclusions and exclusions checklist
  • Exhibit 06: Market size 2017
  • Exhibit 07: Validation techniques employed for market sizing 2017
  • Exhibit 08: Global endometrial cancer therapeutics market - Market size and forecast 2017-2022 ($ bn)
  • Exhibit 09: Global endometrial cancer therapeutics market - Year-over-year growth 2018-2022 (%)
  • Exhibit 10: Five forces analysis 2017
  • Exhibit 11: Five forces analysis 2022
  • Exhibit 12: Bargaining power of buyers
  • Exhibit 13: Bargaining power of suppliers
  • Exhibit 14: Threat of new entrants
  • Exhibit 15: Threat of substitutes
  • Exhibit 16: Threat of rivalry
  • Exhibit 17: Market condition - Five forces 2017
  • Exhibit 18: Pipeline landscape by development phase 2017-2018
  • Exhibit 19: Key clinical trials
  • Exhibit 20: Global endometrial cancer therapeutics market - Market share by product 2017-2022 (%)
  • Exhibit 21: Comparison by product
  • Exhibit 22: Chemotherapy - Market size and forecast 2017-2022 ($ bn)
  • Exhibit 23: Chemotherapy - Year-over-year growth 2018-2022 (%)
  • Exhibit 24: Hormone therapy - Market size and forecast 2017-2022 ($ bn)
  • Exhibit 25: Hormone therapy - Year-over-year growth 2018-2022 (%)
  • Exhibit 26: Market opportunity by product
  • Exhibit 27: Customer landscape
  • Exhibit 28: Global endometrial cancer therapeutics market - Market share by geography 2017-2022 (%)
  • Exhibit 29: Regional comparison
  • Exhibit 30: Americas - Market size and forecast 2017-2022 ($ bn)
  • Exhibit 31: Americas - Year-over-year growth 2018-2022 (%)
  • Exhibit 32: Top 3 countries in Americas
  • Exhibit 33: EMEA - Market size and forecast 2017-2022 ($ bn)
  • Exhibit 34: EMEA - Year-over-year growth 2018-2022 (%)
  • Exhibit 35: Top 3 countries in EMEA
  • Exhibit 36: APAC - Market size and forecast 2017-2022 ($ bn)
  • Exhibit 37: APAC - Year-over-year growth 2018-2022 (%)
  • Exhibit 38: Top 3 countries in APAC
  • Exhibit 39: Market opportunity
  • Exhibit 40: Vendor landscape
  • Exhibit 41: Landscape disruption
  • Exhibit 42: Vendors covered
  • Exhibit 43: Vendor classification
  • Exhibit 44: Market positioning of vendors
  • Exhibit 45: CELGENE - Overview
  • Exhibit 46: CELGENE - Business segments
  • Exhibit 47: CELGENE - Organizational developments
  • Exhibit 48: CELGENE - Geographic focus
  • Exhibit 49: CELGENE - Key offerings
  • Exhibit 50: CELGENE - Key customers
  • Exhibit 51: Janssen Pharmaceuticals - Overview
  • Exhibit 52: Janssen Pharmaceuticals - Business segments
  • Exhibit 53: Janssen Pharmaceuticals - Organizational developments
  • Exhibit 54: Janssen Pharmaceuticals - Geographic focus
  • Exhibit 55: Janssen Pharmaceuticals - Segment focus
  • Exhibit 56: Janssen Pharmaceuticals - Key offerings
  • Exhibit 57: Janssen Pharmaceuticals - Key customers
  • Exhibit 58: Novartis - Overview
  • Exhibit 59: Novartis - Business segments
  • Exhibit 60: Novartis - Organizational developments
  • Exhibit 61: Novartis - Geographic focus
  • Exhibit 62: Novartis - Segment focus
  • Exhibit 63: Novartis - Key offerings
  • Exhibit 64: Novartis - Key customers
  • Exhibit 65: Pfizer - Overview
  • Exhibit 66: Pfizer - Business segments
  • Exhibit 67: Pfizer - Organizational developments
  • Exhibit 68: Pfizer - Geographic focus
  • Exhibit 69: Pfizer - Segment focus
  • Exhibit 70: Pfizer - Key offerings
  • Exhibit 71: Pfizer - Key customers
  • Exhibit 72: Teva Pharmaceutical Industries - Overview
  • Exhibit 73: Teva Pharmaceutical Industries - Business segments
  • Exhibit 74: Teva Pharmaceutical Industries - Organizational developments
  • Exhibit 75: Teva Pharmaceutical Industries - Geographic focus
  • Exhibit 76: Teva Pharmaceutical Industries - Segment focus
  • Exhibit 77: Teva Pharmaceutical Industries - Key offerings
  • Exhibit 78: Teva Pharmaceutical Industries - Key customers